Oesophageal carcinoma
Not recruitingStudy of trastuzumab with chemotherapy and immunotherapy combination for first-line treatment in patients with HER2-positive esophageal squamous cell cancer
Study of trastuzumab with chemotherapy and immunotherapy combination for first-line treatment in patients with HER2-positive esophageal squamous cell cancer
- Disease:Oesophageal carcinoma
- Substances:CapecitabineFluorouracil+3
Denmark- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Frederiksberg Hospital






